| [1] |
Shao CP, Mass JH, Su YQ, et al. Molecular background of Rh D-positive, D-negative, D(el) and weak D phenotypes in Chinese[J]. Vox Sang, 2002, 83(2): 156-161.
|
| [2] |
Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review[J]. Obstet Gynecol, 2012, 120(5): 1132-1139.
|
| [3] |
邵超鹏，秦建江，孙国栋，等. Rh阳性个体RHD杂合性分析[J]. 中华医学遗传学杂志，2011, 28(1): 29-32.
|
| [4] |
Achargui S, Benchemsi N. A quantitative determination of IgG anti-D subclasses by Elisa in hemolytic disease of the newborn[J]. Transfus Clin Biol, 2003, 10(4): 284-291.
|
| [5] |
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 75: management of alloimmunization during pregnancy[J]. Obstet Gynecol, 2006, 108(2): 457-464.
|
| [6] |
韩梅宁，马兆霞，张明刚. 126例Rh阴性妇女D抗原刺激后血清抗体分析[J]. 现代检验医学杂志，2009, 24(2): 125-127.
|
| [7] |
苏奶助，沈雨青，龚君顺，等. 厦门地区RhD阴性孕产妇血清学表型及不规则抗体监测的研究[J]. 临床血液学杂志，2016, 29(3): 471-473.
|
| [8] |
Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage[J]. Obstet Gynecol, 2007, 110(2 Pt 1): 256-260.
|
| [9] |
Kulinska R. Haemolytic disease of the fetus and newborn/HDFN/timing in pregnant women and prophylaxis[J]. Akush Ginekol (Sofiia), 2014, 53(2): 58-63.
|
| [10] |
Shao CP, Xu H, Xu Q, et al. Antenatal Rh prophylaxis is unnecessary for " Asia type" DEL women[J]. Transfus Clin Biol, 2010, 17(4): 260-264.
|
| [11] |
Wang M, Wang BL, Xu W, et al. Anti-D alloimmunisation in pregnant women with DEL phenotype in China[J]. Transfus Med, 2015, 25(3): 163-169.
|
| [12] |
Kapur R, Della Valle L, Sonneved M, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn[J]. Br J Haematol, 2014, 166(6): 936-945.
|
| [13] |
危燕芬，严康峰，汪丽娟，等. 单核单层实验在Rh系统新生儿溶血病中的应用[J]. 国际检验医学杂志，2008, 29(6): 496-497, 500.
|
| [14] |
Mari G, Norton ME, Stone J. et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia-diagnosis and management[J]. Am J Obstet Gynecol, 2015, 212(6): 697-710.
|
| [15] |
Mari G, Deter RL, Carpenter RL, et al. Non-invasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses[J]. N Engl J Med, 2000, 342(1): 9-14.
|
| [16] |
Maisonneuve E, Jayot A, Friszer S, et al. Accuracy of middle cerebral artery doppler assessment between 34 and 37 weeks in fetuses with red cell alloimmunization[J]. Fetal Diagn Ther, 2017, 42(3): 225-231.
|
| [17] |
Avent ND, Reid ME. The Rh blood group system: a review[J]. Blood, 2000, 95(2): 375-387.
|
| [18] |
赵黎，黄醒华. 孕妇输血史与围产儿Rh溶血病的关系[J]. 中华妇产科杂志，1999, 34(4): 45-46.
|
| [19] |
De Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RhD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the netherlands[J]. BMJ, 2016, 355(3): i5789.
|
| [20] |
Mackie FL, Hemming K, Allen S, et al. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate Meta-analysis[J]. BJOG, 2017, 124(1): 32-46.
|
| [21] |
Soothill PW, Finning K, Latham T, et al. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS[J]. BJOG, 2015, 122(12): 1682-1686.
|
| [22] |
Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimmunization[J]. J Obstet Gynaecol Can, 2003, 25(9): 765-773.
|
| [23] |
Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J]. Transfus Med, 2014, 24(1): 8-20.
|
| [24] |
Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015: 146-151.
|
| [25] |
Harrod KS, Hanson L, Vandevusse L, et al. Rh negative status and isoimmunization update: a case-based approach to care[J]. J Perinat Neonatal Nurs, 2003, 17(3): 166-178.
|
| [26] |
Lindenburg IT, van Kamp IL, van Zwet EW, et al. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation[J]. BJOG, 2013, 120(7): 847-852.
|
| [27] |
Papantoniou N, Sifakis S, Antsaklis A. Therapeutic management of fetal anemia: review of standard practice and alternative treatment options[J]. J Perinat Med, 2013, 41(1): 71-82.
|
| [28] |
van Klink JM, van Veen SJ, Smits-Wintjens VE, et al. Immunoglobulins in neonates with rhesus hemolytic disease of the fetus and newborn：long-term outecome in a randomized trial[J]. Fetal Diagn Ther, 2016, 39(3): 209-313.
|
| [29] |
Louis D, More K, Oberoi S, et al. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and Meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2014, 99(4): 325-331.
|
| [30] |
Scheier M, Hernandez-Andrade E, Fonseca EB, et al. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions[J]. Am J Obstet Gynecol, 2006, 195(6): 1550-1556.
|
| [31] |
Payam Khaja Pasha R, Shokri F. Immunologic basis and immunoprophylaxis of Rh(D) induced hemolytic disease of the newborn(HDN)[J]. Iran J Immunol, 2008, 5(4): 181-189.
|